Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability of valsartan in hypertensive children with or without chronic kidney disease
2009-017594-37Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of valsartan in hypertension (HTN) and chronic kidney disease (CKD), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability. Started Apr 2011; status: completed.
02
Drugs
valsartan
03
Conditions
hypertension (HTN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2009-017594-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017594-37.